APGE Apogee Therapeutics
Price Chart
Executive Summary
Apogee Therapeutics announced positive 52-week maintenance data from Part A of its Phase 2 APEX trial for zumilokibart (APG777), an anti-IL-13 antibody in moderate-to-severe atopic dermatitis. The drug showed durable and deepening responses with every 3- and 6-month dosing, supporting its potential as a best-in-class therapy with infrequent dosing. Phase 3 trials are expected to begin in the second half of 2026, with a potential 2029 commercial launch.
Actionable Insight
Traders should monitor the upcoming APEX Part B 16-week induction data in 2Q 2026, which will be critical for confirming efficacy and supporting Phase 3 initiation. Positive results could further drive upside given the high unmet need for infrequently dosed AD therapies.
Key Facts
- Zumilokibart demonstrated 75% and 85% maintenance of EASI-75 response at 52 weeks with every 3- and 6-month dosing, respectively.
- vIGA 0/1 response was maintained in 86% (3-month) and 78% (6-month) of Week 16 responders.
- Deepening of response observed across all lesional and itch endpoints in the full treated population, not just initial responders.
- Drug was well tolerated with a safety profile consistent with class; most common TEAEs: noninfective conjunctivitis, URTI, nasopharyngitis.
- Phase 3 trials expected to initiate in 2H 2026, with potential commercial launch in 2029.
Financial Impact
No direct financial figures reported, but successful Phase 2 data de-risks development and increases probability of regulatory approval and commercial success.
Risk Factors
- Phase 3 trials have not yet started; clinical success in Phase 2 does not guarantee Phase 3 outcomes.
- Competition from existing and emerging IL-13/IL-4 inhibitors (e.g., dupilumab, tralokinumab) with established market presence.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260201 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
18d ago
|
8-K
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $88.33 (+13.61%) |
|
May 27, 2026
18d ago
|
8-K
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $88.33 (+13.61%) |
|
May 27, 2026
18d ago
|
Press Release
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $88.33 (+13.61%) |
|
May 27, 2026
18d ago
|
Press Release
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $88.33 (+13.61%) |
|
May 26, 2026
19d ago
|
Press Release
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $88.33 (+13.61%) |
|
May 16, 2026
4w ago
|
Insider Cluster
| $78.75 $82.81 | ▲ +5.16% | ▲ +3.54% | $88.33 (+12.17%) |
|
May 13, 2026
4w ago
|
144
| $83.94 $81.39 | ▼ −3.04% | ▼ −2.90% | $88.33 (+5.23%) |
|
May 11, 2026
4w ago
|
8-K
| $84.60 $78.75 | ▼ −6.91% | ▼ −6.83% | $88.33 (+4.41%) |
|
May 11, 2026
4w ago
|
Press Release
| $84.60 $78.75 | ▼ −6.91% | ▼ −6.83% | $88.33 (+4.41%) |
|
May 1, 2026
6w ago
|
Insider Cluster
| $80.75 $83.03 | ▲ +2.82% | ▲ +0.48% | $88.33 (+9.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access